Member Profile

Dr. Manuel D Carcao
MD, MSc

Manuel D. Carcao received his medical training from the University of Toronto, Canada, graduating in 1990. In 2007 he received a Masters of Science degree in Clinical Epidemiology at the same institution. He is currently a staff paediatric haematologist/oncologist in the Division of Haematology/Oncology and an Associate Professor in the Dept of Paediatrics at The Hospital for Sick Children in Toronto. He is also Co-Director of the Comprehensive Care Paediatric Haemophilia Clinic and an Associate Scientist/Clinician Investigator in the hospital’s research institute.

 

Dr. Carcao’s research interests are in the study of congenital bleeding disorders (haemophilia, VWD and rare inherited coagulation and platelet disorders) and in particular the study of inter-patient disease variability with respect to inhibitor development, prophylaxis needs and pharmacokinetics. Dr. Carcao also has a substantial clinical and research interests in childhood immune thrombocytopenia and hereditary spherocytosis.

 

Dr. Carcao was President of the Association of Hemophilia Clinic Directors of Canada from 2006 to 2008 and currently is the Chair of its Inhibitor Subcommittee. He was on the Board of Directors of the Haemophilia and Thrombosis Research Society of North America (2010-13). He is secretary of the Canadian Paediatric Thrombosis and Haemostasis Network and is an active member of the International Prophylaxis Study Group (IPSG) serving in various capacities. He is on the editorial board of several well known journals. He has been an invited lecturer on many occasions, and is the author or co-author of numerous peer-reviewed papers and textbook chapters.

Key Publications

1. Carcao M. Changing paradigm of prophylaxis with longer acting factor concentrates. Haemophilia 2014; 20 (Suppl. 4):99-105. (C/T)

2. Gouw SC, van den Berg HM, Fischer K, Auerswald G, Carcao M, Chalmers E, Chambost H, Kurnik K, Liesner R, Petrini P, Platokouki H, Altisent C, Oldenburg J, Nolan B, Pérez Garrido R, Mancuso ME, Rafowicz A, Williams M, Clausen N, Middelburg RA, Ljung R, van der Bom JG. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013. May 16; 121(20):4046-55. (R)

3. Carcao M, Van den Berg HM, Ljung R, Mancuso ME. Correlation between Phenotype and Genotype in a large unselected cohort of children with severe Haemophilia A. Blood. 2013 May 9; 121(19):3946-52 (R)

4. Feldman BM, Berger K, Bohn R, Carcao MD, Fischer K, Gringeri A, Hoots K, Mantovani L, Willan A, Schramm W. Hemophilia Prophylaxis: How can we justify the costs? Hemophilia 2012; Sept; 18(5):680-684. (C)

5. Carcao MD. Side Effects and Venous Access Issues with Immune tolerance therapy. Haemophilia 2009; 15(2):494-500. (C)

Current Positions/Chairs:

  • Member
    International Prophylaxis Study Group- Prophylaxis Expert Working Group
  • Paediatric Haematologist/ Oncologist
    Division of Haematology/ Oncology
  • Associate Professor
    Department of Paediatrics at the Hospital for Sick Children
  • Co-Director
    Comprehensive Care Paediatric Haemophilia Clinic
  • Associate Scientist/ Clinician Investigator
    Research Institute at the Hospital for Sick Children
  • Chair
    Inhibitor Subcommittee of the Association of Hemophilia Clinic Directors of Canada
  • Secretary
    Canadian Paediatric Thrombosis and Haemostasis Network

Key Institutions

  • The Hospital for Sick Children
    Division of Haematology/ Oncology
    Toronto, Canada

Research Interests

  • Congenital bleeding disorders (haemophilia, VWD and rare-inherited coagulation and platelet disorders)
  • Inter-patient disease variability with respect to inhibitor development, prophylaxis needs and pharmacokinetics
  • Childhood immune thrombocytopenia and hereditary spherocytosis

Publications

April 24, 2017

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia

Authors
Carcao MD, Avila L, Leissinger C, Blanchette VS, Aledort L; Factor Utilization Expert Working Group on behalf of the International Prophylaxis Study Group (IPSG) and participating Survey Investigators.
Citation
Haemophilia 2017; 23 (5) : e444 - e447
April 21, 2017

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia

Authors
Carcao M, Avila L, Leissinger C, Blanchette VS, and Aledort LM on behalf of the Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and participating Survey Investigators
Citation
Haemophilia 2017; 23 (5): e447 - e450
December 3, 2015

Hemophilia prophylaxis no longer just for children without inhibitors – increasing use of prophylaxis in other groups (children with inhibitors and adults with and without inhibitors)

Authors
Carcao M, Avila L, Blanchette V, Santagostino E, Escuriola-Ettingshausen C, Leissinger C, Lambert T, Aledort L on behalf of the International Prophylaxis Study Group (IPSG) and Survey Investigators.
Citation
Blood 2015; 126: 3535
June 20, 2015

Prophylaxis practices in children and adults with inhibitors

The XXV Congress of the International Society on Thrombosis and Haemostasis (June 20 - 25, 2015 – Toronto, Canada)
Authors
Carcao M, Avila M, Aledort L, Leissinger C on behalf of Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and other Survey Investigators
Citation
June 20, 2015

Prophylaxis in adult patients with severe hemophilia A or B without inhibitors.

The XXV Congress of the International Society on Thrombosis and Haemostasis (June 20–25, 2015 – Toronto, Canada)
Authors
Carcao, M on behalf of Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and other Survey Investigators.
Citation